Boston Scientific Corp

BSXNYSE · USD
44.34USD0.00 (+0.32%)
772

Boston Scientific Corp (BSX) Covered Calls

Boston Scientific Corp trades in the Medical Devices industry with an IV Rank of 99.60%, high versus the past year. BSX's highest covered call setup is the $47.50 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 7.13% out of the money with 7 days to expiration, a 7.24% return until expiration, and a 377.49% theoretical annualized return. Across the setups shown, annualized returns run from 226.67% to 377.49% at strikes between $46.50 and $65.00, with 7 to 63 days to expiration, as of Nov 13, 2026.

Read more

Running BSX covered calls helps you generate income from Boston Scientific Corp shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best BSX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If BSX stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling BSX covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given BSX covered call is worth writing.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems.

2026-11-20747.507.130.050.35321.007.24377.49-0.11+0.142020.30
2026-11-20747.006.000.100.30276.006.22324.57-0.23+0.168040.20
2026-11-271449.0010.510.050.15471.0010.62276.94-0.11+0.081260.10
2027-01-156365.0046.590.050.152071.0046.71270.61-0.11+0.0314,2940.10
2026-11-20746.504.870.100.35226.005.10265.77-0.23+0.195440.25
2026-12-042151.0015.020.050.20671.0015.13263.03-0.11+0.07330.15
2026-12-183555.0024.040.050.151071.0024.15251.89-0.11+0.056,5630.10
2026-11-271448.509.380.100.40426.009.61250.48-0.23+0.1420.30
2026-12-042150.0012.760.150.40581.0013.10227.75-0.34+0.133480.25
2026-12-112852.0017.280.050.35771.0017.39226.67-0.11+0.0980.30

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryMedical Devices
  • SectorHealthcare
  • IV Rank99.60% High
  • Market cap (M$)64,270
  • 52 weeks high-57.62%
  • 52 weeks low12.05%
  • Analyst recommendationBuy
    1.78
  • Target price$49.93
    12.61% above the current stock price
  • Dividend—
  • Payout ratio0.00%
  • Earnings date2027-02-03
  • P/E18.77
  • Future P/E14.20
  • EPS (ttm)2.36
  • EPS growth next 5 years3.11%

As of Nov 13, 2026